http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-20090100147-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e4de608e00ae4c35e3421e0ade664ef |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 |
| filingDate | 2009-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b79325363fd12d068af9a076fa95bcfe |
| publicationDate | 2010-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GR-20090100147-A |
| titleOfInvention | EXTREMELY SIGNIFICANT ANTI-CANCER ACTION: MENYLENE CINARCIN AND BLUE |
| abstract | The present invention discloses the chemical affinity of quinacrine (CNC) and methylene blue (MB) and its resulting anticancer activity, monotherapeutically, and most importantly - in the basic concept of the invention - synergistically, between them, and with In both cases, there is an increase in anticancer activity and, in the case of co-administration of MB, a reduction in the toxicity of CNS and CFS and, in the case of CFS, additional protection against it. neuropathic pain, caused by most NSAIDs, and more specifically, the most effective (Paclitaxel, Platinum, Vincristine). |
| priorityDate | 2009-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.